Journey Medical Corp. DERM 深 沪
等待开盘 08-08 09:30:00 美东时间
7.30
+0.070
+0.97%
华盛通- 最 高7.39
- 今 开7.27
- 成交量 13.92万股
- 最 低 7.06
- 昨 收 7.23
- 总市值 1.70亿
- 52周最高 8.2487
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 3.535
- 委 比 -6.67%
- 总股本 2329.58万
- 历史最高 10.20
- 量 比 1.73
- 振 幅 4.56%
- 历史最低 1.02
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
Journey Medical Corporation will ring the Nasdaq closing bell on August 11, 2025, to celebrate its 4-year anniversary as a publicly traded company and the commercial launch of Emrosi™ for rosacea treatment. Claude Maraoui, CEO, highlighted the company's progress and confidence in Emrosi's success to drive profitability and positive EBITDA this year. A live stream of the event will be available.
08-07 12:30
Get Ready, JUVÉDERM® Day is Calling!
Allergan Aesthetics Celebrates Third Annual JUVÉDERM® Day with BOGO Gift Cards and $10,000 Sweepstakes Join Allē Today to Take Advantage of Limited-Time Offers, While Supplies Last IRVINE, C...
08-06 20:00
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Journey Medical Corporation (Nasdaq: DERM) announced it will release its second quarter 2025 financial results on August 12, 2025, after U.S. markets close. A conference call and audio webcast will follow at 4:30 p.m. ET on the same day. Interested parties can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) or register via the provided link. The webcast will be available on the company’s website and remain archived for 30 days. J...
08-05 20:01
B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $12
B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $12.
07-30 23:51
Journey Medical's Emrosi Now Covered For 65% Of U.S. Commercial Lives, Up From 29% In May
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increaseSCOTTSDALE, Ariz.,
07-14 20:35
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Journey Medical Corporation announced that 65% of commercial lives in the United States now have pharmacy benefit coverage for Emrosi™, its treatment for rosacea, up from 29% in May 2025. The expanded coverage is expected to drive further growth in prescription demand. Emrosi™, a novel treatment for inflammatory lesions of rosacea, has shown superior efficacy over current standards. The company is focused on improving patient access and believes ...
07-14 12:30
AbbVie's Allergan Aesthetics Announces That The U.S. FDA Accepted For Review The SPMA Application For SKINVIVE By JUVÉDERM To Reduce Neck Lines For The Improvement Of Neck Appearance In Adults Over The Age Of 21
SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness.If approved, SKINVIVE by JUVÉDERM® will be
06-30 20:29
Journey Medical Joins Russell 2000 and 3000 Indices
An announcement from Journey Medical Corp ( ($DERM) ) is now available. On June...
06-24 20:58
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
Journey Medical Corporation, a dermatology-focused pharmaceutical company, announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 27, 2025. CEO Claude Maraoui highlighted the potential increase in investor visibility and discussed the strong launch of their FDA-approved product, Emrosi™, for rosacea. The Russell 3000® Index includes the largest 3,000 U.S. companies by market cap, while the Russell 2000® Index focuse...
06-24 12:30
